BioRestorative Therapies (BRTX) Total Current Liabilities (2010 - 2025)

BioRestorative Therapies (BRTX) has reported Total Current Liabilities for 16 consecutive years, with $3.7 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Total Current Liabilities fell 0.68% year-over-year to $3.7 million; the trailing twelve-month figure through Dec 2025 stood at $3.7 million (down 0.68% YoY), and the FY2025 full-year result was $3.7 million, down 0.68% from the prior year.
• Total Current Liabilities rose to $3.7 million in Q4 2025 per BRTX's latest filing, from $3.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $14.7 million in Q1 2022 and bottomed at $363822.0 in Q4 2021.
• Historically, Total Current Liabilities has averaged $4.8 million across 5 years, with a median of $3.7 million in 2024.
• The sharpest annual moves came in 2021 and 2022: Total Current Liabilities slumped 92.99% in 2021, then soared 1544.22% in 2022.
• Over 5 years, Total Current Liabilities stood at $363822.0 in 2021, then jumped by 1544.22% to $6.0 million in 2022, then sank by 56.41% to $2.6 million in 2023, then jumped by 43.76% to $3.7 million in 2024, then fell by 0.68% to $3.7 million in 2025.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $3.7 million, $3.4 million, and $3.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.